Scientific and Regulatory Policy Committee Points to Consider: Biological Sample Retention From Nonclinical Toxicity Studies.

Good Laboratory Practice body fluid clinical pathology formalin fixed paraffin-embedded sample retention sample stability toxicologic pathology

Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
02 2022
Historique:
pubmed: 28 10 2021
medline: 5 4 2022
entrez: 27 10 2021
Statut: ppublish

Résumé

Samples of biologic specimens and their derivatives (eg, wet tissues, paraffin-embedded tissue blocks, histology slides, frozen tissues, whole blood, serum/plasma, and urine) are routinely collected during the course of nonclinical toxicity studies. Good Laboratory Practice regulations and/or guidance specify minimum requirements for specimen retention duration, with the caveat that retention of biologic specimens need not extend beyond the duration of sample stability. However, limited availability of published data regarding stability for various purposes following storage of each specimen type has resulted in confusion, uncertainty, and inconsistency as to the appropriate duration for storage of these specimens. To address these issues, a working group of the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee was formed to review published information, regulations, and guidance pertinent to this topic and to summarize the current practices and rationales for retention duration through a survey-based approach. Information regarding experiences reaccessing biologic specimens and performing sample stability investigations was also collected. Based on this combined information, the working group developed several points to consider that may be referenced when developing or revising sample retention practices. [Box: see text].

Identifiants

pubmed: 34702102
doi: 10.1177/01926233211049156
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-265

Auteurs

Carole E Harbison (CE)

Takeda Pharmaceuticals, Cambridge, MA, USA.

Adam D Aulbach (AD)

Inotiv, Maryland Heights, MO, USA.

Bindu M Bennet (BM)

Relay Therapeutics, Cambridge, MA, USA.

Molly H Boyle (MH)

Covance Laboratories, Somerset, NJ, USA.

Mary E Carsillo (ME)

Takeda Pharmaceuticals, Cambridge, MA, USA.

Torrie A Crabbs (TA)

Experimental Pathology Laboratories, Research Triangle Park, NC, USA.

Natalie D Keirstead (ND)

Merck & Co., Inc., Kenilworth, NJ, USA.

Krista M D La Perle (KMD)

Comparative Pathology & Digital Imaging Shared Resource, Ohio State University, Columbus, OH, USA.

Arun R Pandiri (AR)

Cellular and Molecular Pathology Branch, Division of National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.

Ahmed M Shoieb (AM)

Drug Safety R&D, Pfizer Worldwide RD&M, Groton, CT, USA.

William D Siska (WD)

Charles River Laboratories Inc., Reno, NV, USA.

Articles similaires

Humans Self-Control Longitudinal Studies Child, Preschool Child

Why experimental variation in neuroimaging should be embraced.

Gregory Kiar, Jeanette A Mumford, Ting Xu et al.
1.00
Humans Neuroimaging Brain Reproducibility of Results Magnetic Resonance Imaging

Classifications MeSH